9R80 Stock Overview

A research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. More details

9R80 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Revenue is forecast to grow 112.2% per year

Earnings have grown 11.8% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Negative shareholders equity

Makes less than USD$1m in revenue ($16K)

Shareholders have been substantially diluted in the past year

+ 2 more risks

My Notes

Capture your thoughts, links and company narrative

ZIVO Bioscience, Inc. Competitors

Pharmsville

KOSDAQ:A318010

₩30.5b

Peregrine Industries

OTCPK:PGID

US$22.7m

Nova Organic

SET:NV

฿489.6m

Fourace Industries Group Holdings

SEHK:1455

HK$198.2m

Price History & Performance

Summary of share price highs, lows and changes for ZIVO Bioscience
Historical stock prices
Current Share Price	US$3.63
52 Week High	US$13.68
52 Week Low	US$3.63
Beta	0.021
1 Month Change	0%
3 Month Change	-0.82%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-82.71%

Recent updates

Shareholder Returns

	9R80	DE Personal Products	DE Market
7D	0%	-2.0%	-2.6%
1Y	n/a	-7.7%	6.9%

Return vs Industry: Insufficient data to determine how 9R80 performed against the German Personal Products industry.

Return vs Market: Insufficient data to determine how 9R80 performed against the German Market.

Price Volatility

Is 9R80's price volatile compared to industry and market?
9R80 volatility
9R80 Average Weekly Movement	n/a
Personal Products Industry Average Movement	3.8%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.3%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 9R80 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 9R80's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	8	John Payne	www.zivobioscience.com

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging.

ZIVO Bioscience, Inc. Fundamentals Summary

How do ZIVO Bioscience's earnings and revenue compare to its market cap?
9R80 fundamental statistics
Market cap	€21.65m
Earnings (TTM)	-€7.80m
Revenue (TTM)	€14.53k

1,490x

P/S Ratio

-2.8x

P/E Ratio

Is 9R80 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
9R80 income statement (TTM)
Revenue	US$15.85k
Cost of Revenue	US$8.37k
Gross Profit	US$7.48k
Other Expenses	US$8.52m
Earnings	-US$8.51m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-3.10
Gross Margin	47.19%
Net Profit Margin	-53,687.27%
Debt/Equity Ratio	-125.2%

How did 9R80 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/01/23 16:40
End of Day Share Price	2023/10/26 00:00
Earnings	2023/09/30
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ZIVO Bioscience, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Anthony Vendetti	Maxim Group